Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. 2017

Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York, NY. Electronic address: ama146@cumc.columbia.edu.

OBJECTIVE This review of the scientific literature examines the potential adult sequelae of exposure to cannabis and related synthetic cannabinoids in adolescence. We examine the four neuropsychiatric outcomes that are likely most vulnerable to alteration by early cannabinoid use, as identified within both the clinical and preclinical research: cognition, emotional functioning, risk for psychosis, and addiction. METHODS A literature search was conducted through PubMed, PsychInfo, and Google Scholar with no publication date restrictions. The search terms used were "adolescent" and "adult," and either "cannabis," "marijuana," "delta-9-tetra-hydrocannabinol," or "cannabinoid," which was then crossed with one or more of the following terms: "deficit," "impairment," "alteration," "long-term," "persistent," "development," "maturation," and "pubescent." RESULTS The majority of the clinical and preclinical data point to a strong correlation between adolescent cannabinoid exposure and persistent, adverse neuropsychiatric outcomes in adulthood. Although the literature supports the hypothesis that adolescent cannabis use is connected to impaired cognition and mental health in adults, it does not conclusively demonstrate that cannabis consumption alone is sufficient to cause these deficits in humans. The animal literature, however, clearly indicates that adolescent-onset exposure to cannabinoids can catalyze molecular processes that lead to persistent functional deficits in adulthood, deficits that are not found to follow adult-onset exposure and that model some of the adverse outcomes reported in humans among adult populations of early-onset cannabis users. CONCLUSIONS Based on the data in the current literature, a strong association is found between early, frequent, and heavy adolescent cannabis exposure and poor cognitive and psychiatric outcomes in adulthood, yet definite conclusions cannot yet be made as to whether cannabis use alone has a negative impact on the human adolescent brain. Future research will require animal models and longitudinal studies to be carefully designed with a focus on integrating assessments of molecular, structural, and behavioral outcomes in order to elucidate the full range of potential adverse and long-term consequences of cannabinoid exposure in adolescence.

UI MeSH Term Description Entries
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D002186 Cannabinoids Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Cannabinoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074609 Marijuana Use Medicinal or recreational utilization of MARIJUANA. Marijuana-Related Disorder,Recreational Marijuana Use,Disorder, Marijuana-Related,Disorders, Marijuana-Related,Marijuana Related Disorder,Marijuana Use, Recreational,Marijuana Uses,Marijuana Uses, Recreational,Marijuana-Related Disorders,Recreational Marijuana Uses,Use, Marijuana,Use, Recreational Marijuana,Uses, Marijuana,Uses, Recreational Marijuana
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000342 Affective Symptoms Mood or emotional responses dissonant with or inappropriate to the behavior and/or stimulus. Alexithymia,Emotional Disturbances,Affective Symptom,Alexithymias,Disturbance, Emotional,Disturbances, Emotional,Emotional Disturbance,Symptom, Affective,Symptoms, Affective
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D060825 Cognitive Dysfunction Diminished or impaired mental and/or intellectual function. Cognitive Disorder,Mild Cognitive Impairment,Cognitive Decline,Cognitive Impairments,Mental Deterioration,Cognitive Declines,Cognitive Disorders,Cognitive Dysfunctions,Cognitive Impairment,Cognitive Impairment, Mild,Cognitive Impairments, Mild,Decline, Cognitive,Declines, Cognitive,Deterioration, Mental,Deteriorations, Mental,Disorder, Cognitive,Disorders, Cognitive,Dysfunction, Cognitive,Dysfunctions, Cognitive,Impairment, Cognitive,Impairment, Mild Cognitive,Impairments, Cognitive,Impairments, Mild Cognitive,Mental Deteriorations,Mild Cognitive Impairments
D019966 Substance-Related Disorders Disorders related to substance use or abuse. Chemical Dependence,Drug Abuse,Drug Addiction,Drug Dependence,Drug Habituation,Drug Use Disorder,Drug Use Disorders,Organic Mental Disorders, Substance-Induced,Substance Abuse,Substance Dependence,Substance Related Disorder,Substance Use,Substance Use Disorder,Substance Use Disorders,Prescription Drug Abuse,Substance Addiction,Abuse, Drug,Abuse, Prescription Drug,Abuse, Substance,Addiction, Drug,Addiction, Substance,Chemical Dependences,Dependence, Chemical,Dependence, Drug,Dependence, Substance,Dependences, Chemical,Disorder, Drug Use,Disorder, Substance Related,Disorder, Substance Use,Disorders, Substance Related,Drug Abuse, Prescription,Habituation, Drug,Organic Mental Disorders, Substance Induced,Related Disorder, Substance,Related Disorders, Substance,Substance Abuses,Substance Uses,Use, Substance

Related Publications

Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
July 1976, Population reports. Series J, Family planning programs,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
September 1999, Advance for nurse practitioners,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
December 2019, Trends in neurosciences,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
February 2019, Occupational and environmental medicine,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
February 2006, PLoS medicine,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
January 2014, Alcohol and alcoholism (Oxford, Oxfordshire),
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
January 2021, Frontiers in psychology,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
March 1999, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
May 2021, International journal of environmental research and public health,
Amir Levine, and Kelly Clemenza, and Moira Rynn, and Jeffrey Lieberman
March 2015, Journal of neonatal-perinatal medicine,
Copied contents to your clipboard!